The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

Speaking at the World Economic Forum in Davos, Donald Trump said tariffs helped fix the long-time drug pricing scam in the US ...

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

Regene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating PD.

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

Bristol Myers Squibb (BMS) has entered into an agreement with Microsoft to advance AI-driven early lung cancer detection.

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

As more drugs go subcutaneous, Phillips Medisize's Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...